<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668521</url>
  </required_header>
  <id_info>
    <org_study_id>05-2019</org_study_id>
    <nct_id>NCT04668521</nct_id>
  </id_info>
  <brief_title>Multifactorial Risk Assessment for Breast &amp; Ovarian Cancer Risk Detection</brief_title>
  <acronym>OVA360</acronym>
  <official_title>Multifactorial Risk Assessment for Breast &amp; Ovarian Cancer Risk Detection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aspira Women's Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aspira Women's Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this project is to validate a next-generation assay that utilizes both the&#xD;
      protein biomarkers of our already established ovarian cancer risk assessment combined with a&#xD;
      molecular profile in both germline and early somatic detection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OVA360</measure>
    <time_frame>12 months</time_frame>
    <description>Identify the molecular key driver of Ovarian cancer and develop a diagnostic test for early Ovarian cancer detection</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Adnexal Mass</condition>
  <condition>Germline BRCA1 Gene Mutation</condition>
  <condition>Germline BRCA2 Gene Mutation</condition>
  <condition>Hereditary Breast and Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>COHORT A</arm_group_label>
    <description>Women with a pelvic mass, symptomatic or asymptomatic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COHORT B</arm_group_label>
    <description>Women diagnosed with a pelvis mass undergoing genetic testing through our commercial offering.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COHORT C</arm_group_label>
    <description>Subject must not have an identifiable adnexal mass and may, or may not, have a family history or a known familial genetic abnormality (germ line or identified in family cancer i.e. somatic DNA mutation) associated with ovarian cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OVA360</intervention_name>
    <description>Multifactorial Risk Assessment for Breast &amp; Ovarian Cancer Risk Detection</description>
    <arm_group_label>COHORT A</arm_group_label>
    <arm_group_label>COHORT B</arm_group_label>
    <arm_group_label>COHORT C</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with or without a pelvic mass.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key inclusion criteria:&#xD;
&#xD;
          -  Female subject&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
        Cohort A specific inclusion criteria:&#xD;
&#xD;
        • Diagnosed with a pelvic mass&#xD;
&#xD;
        Cohort B specific inclusion criteria:&#xD;
&#xD;
          -  Diagnosed with a pelvic mass&#xD;
&#xD;
          -  Undergoing genetic testing through our commercial offering&#xD;
&#xD;
        Cohort C specific inclusion criteria:&#xD;
&#xD;
        • Subject must not have an identifiable adnexal mass and may, or may not, have a family&#xD;
        history or a known familial genetic abnormality (germ line or identified in family cancer&#xD;
        i.e. somatic DNA mutation) associated with ovarian cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  n/a&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lesley Northrop, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aspira Women's Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Rana</last_name>
    <phone>8606814310</phone>
    <email>JRANA@ASPIRAWH.COM</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aspira Women's Health</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Rana</last_name>
      <phone>860-681-4310</phone>
      <email>JRANA@ASPIRAWH.COM</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Hereditary Breast and Ovarian Cancer Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

